|Assessment Status||Assessment process complete|
|Indication||For the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).|
|Rapid review commissioned||07/11/2014|
|Rapid review completed||18/12/2014|
|Rapid review outcome||Full Pharmacoeconomic Assessment Recommended|
|Full pharmacoeconomic assessment commissioned by HSE||10/04/2015|
|NCPE assessment completed||06/10/2015|
|NCPE assessment outcome||Reimbursement not recommended.|
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with relapsed or refractory MCL has not been demonstrated. Therefore it is not recommended for reimbursement at the submitted price.
The HSE has approved reimbursement following confidential price negotiations.